212 related articles for article (PubMed ID: 34986672)
1. Data from small cell neuroendocrine carcinoma of the cervix: FIGO 2018 staging is more accurate than FIGO 2009.
Zhang Y; Ding J; Hua K
J Int Med Res; 2022 Jan; 50(1):3000605211067397. PubMed ID: 34986672
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
Lee JM; Lee KB; Nam JH; Ryu SY; Bae DS; Park JT; Kim SC; Cha SD; Kim KR; Song SY; Kang SB
Ann Oncol; 2008 Feb; 19(2):321-6. PubMed ID: 17962205
[TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease].
Wang Z; Wu L; Yao H; Sun Y; Li X; Li B; Zhang R; Ma S; Huang M
Zhonghua Fu Chan Ke Za Zhi; 2015 Mar; 50(3):198-203. PubMed ID: 26268410
[TBL] [Abstract][Full Text] [Related]
4. A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix.
Lee SW; Lim KT; Bae DS; Park SY; Kim YT; Kim KR; Nam JH
Gynecol Obstet Invest; 2015; 79(3):172-8. PubMed ID: 25500455
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses.
Lin LM; Lin Q; Liu J; Chu KX; Huang YX; Zhang ZK; Li T; Dai YQ; Li JL
Cancer Med; 2020 Sep; 9(18):6524-6532. PubMed ID: 32705800
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
Feng M; Zou J; Zhang Y; Sun L
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
[No Abstract] [Full Text] [Related]
7. Clinicopathological Aspects of Small Cell Neuroendocrine Carcinoma of the Uterine Cervix: a Multicenter Retrospective Study and Meta-Analysis.
Xu F; Ma J; Yi H; Hu H; Fan L; Wu P; Chen X; Wu X; Yu L; Xing H; Wang W
Cell Physiol Biochem; 2018; 50(3):1113-1122. PubMed ID: 30355937
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study.
Zeng J; Qu P; Hu Y; Sun P; Qi J; Zhao G; Gao Y
Medicine (Baltimore); 2020 Apr; 99(16):e19714. PubMed ID: 32311956
[TBL] [Abstract][Full Text] [Related]
9. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
Pei X; Xiang L; Ye S; He T; Cheng Y; Yang W; Wu X; Yang H
Gynecol Oncol; 2017 Dec; 147(3):589-596. PubMed ID: 28954697
[TBL] [Abstract][Full Text] [Related]
10. The impact of neo/adjuvant treatment choices on prognosis for surgically treated small-cell neuroendocrine carcinoma of the cervix.
Zhao D; Sun S; Yang Z; Wang P; Qiu H
Neoplasma; 2024 Feb; 71(1):70-76. PubMed ID: 38215035
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging-based validation of the 2018 FIGO staging system in patients treated with definitive radiotherapy for locally advanced cervix cancer.
Kim J; Cho Y; Kim N; Chung SY; Kim JW; Lee IJ; Kim YB
Gynecol Oncol; 2021 Mar; 160(3):735-741. PubMed ID: 33358037
[TBL] [Abstract][Full Text] [Related]
13. Small cell carcinoma of the uterine cervix: a multi-institutional experience.
Li J; Ouyang Y; Tao Y; Wang L; Li M; Gao L; Cao X
Int J Gynecol Cancer; 2020 Feb; 30(2):174-180. PubMed ID: 31792086
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors of Surgically Treated Early-Stage Small Cell Neuroendocrine Carcinoma of the Cervix.
Yuan L; Jiang H; Lu Y; Guo SW; Liu X
Int J Gynecol Cancer; 2015 Sep; 25(7):1315-21. PubMed ID: 26186071
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and treatment of neuroendocrine tumors of the uterine cervix based on the FIGO 2018 staging system: a single-institution study of 172 patients.
Chen J; Sun Y; Chen L; Zang L; Lin C; Lu Y; Lin L; Lin A; Dan H; Chen Y; He H
PeerJ; 2021; 9():e11563. PubMed ID: 34268005
[TBL] [Abstract][Full Text] [Related]
16. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation.
Raut A; Chopra S; Mittal P; Patil G; Mahantshetty U; Gurram L; Swamidas J; Ghosh J; Gulia S; Popat P; Deodhar K; Maheshwari A; Gupta S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1248-1256. PubMed ID: 32681859
[TBL] [Abstract][Full Text] [Related]
17. The tumor-stroma ratio is an independent predictor of survival in patients with 2018 FIGO stage IIIC squamous cell carcinoma of the cervix following primary radical surgery.
Zong L; Zhang Q; Kong Y; Yang F; Zhou Y; Yu S; Wu M; Chen J; Zhang Y; Xiang Y
Gynecol Oncol; 2020 Mar; 156(3):676-681. PubMed ID: 31882242
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.
Wright JD; Matsuo K; Huang Y; Tergas AI; Hou JY; Khoury-Collado F; St Clair CM; Ananth CV; Neugut AI; Hershman DL
Obstet Gynecol; 2019 Jul; 134(1):49-57. PubMed ID: 31188324
[TBL] [Abstract][Full Text] [Related]
19. A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes.
Ishikawa M; Kasamatsu T; Tsuda H; Fukunaga M; Sakamoto A; Kaku T; Kato T; Takahashi K; Ariyoshi K; Suzuki K; Arimoto T; Matsumoto Y; Nakai H; Inoue T; Yokoyama M; Kawabata T; Kodama S; Miyamoto T; Takano M; Yaegashi N
Gynecol Oncol; 2019 Dec; 155(3):444-451. PubMed ID: 31635755
[TBL] [Abstract][Full Text] [Related]
20. The local treatment modalities in FIGO stage I-II small-cell carcinoma of the cervix are determined by disease stage and lymph node status.
Zhou J; Yang HY; Wu SG; He ZY; Lin HX; Sun JY; Li Q; Guo ZW
Cancer Med; 2016 Jun; 5(6):1108-15. PubMed ID: 26990881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
